Affiliation:
1. Pharmacy Department , University Hospital , Vandœuvre-lès-Nancy , France
2. Infostab, Non-Profit Association , Heillecourt , France
3. Université de Lorraine , Nancy , France
Abstract
Abstract
Objectives
To the best of our knowledge, few studies have been published on the stability of cabazitaxel in infusion bags. Stabilis® database has selected a study demonstrating the stability of this molecule at 0.15 mg/mL for 28 days at 4 °C and 25 °C in polyolefin bags. The aim of this work was to study the physicochemical stability of Cabazitaxel Zentiva® solutions in vials after “opening” with a vented ChemoClave® Spike, at 25 °C, protected from light and in solutions diluted at 0.1 and 0.26 mg/mL in 0.9 % sodium chloride (0.9 % NaCl) or dextrose 5 % (D5W) in 3 types of infusion bags (Easyflex® and Viaflo® at 25 °C, Freeflex® between 2 and 8 °C, protected from light).
Methods
The chemical stability was analyzed after preparation and then after 14 and 28 days of storage by high performance liquid chromatography (HPLC), coupled to a diode array detector, at the analysis wavelength of 232 nm. The method has been validated according to ICH Q2 (R1) standards. For the study in infusion bags, three preparations were realised for each condition. At each time of analysis, for each bag, a sample was prepared and analyzed by HPLC. Two vials after “openings” were kept at 25 °C and three samples per vial were prepared and analyzed at the three analysis times (D0, D14 and D28). Physical stability was assessed by visual examination (change in colour, appearance of precipitate, gas formation). The pH of the solutions prepared in infusion bags was evaluated at each analysis time.
Results
Cabazitaxel solutions at 0.1 and 0.26 mg/mL diluted in 0.9 % NaCl or D5W in Easyflex® (polyolefin), Viaflo® (multilayer high density polyethylene, polyamide, polypropylene) bags retained more than 95 % of the concentration after 28 days at 25 °C. In the Freeflex® bag (polypropylene multilayers), cabazitaxel solutions at 0.1 and 0.26 mg/mL diluted in 0.9 % NaCl or D5W retained more than 95 % of the initial concentration between 2 and 8 °C for 28 days. In vials with a Spike, cabazitaxel solutions at 20 mg/mL retained more than 95 % of the initial concentration for 28 days at 25 °C. For all the conditions studied, no visual modification was observed. The pH of solutions in bags were constant during the stability study.
Conclusions
Cabazitaxel Zentiva® diluted at 0.1 and 0.26 mg/mL in 0.9 % NaCl or D5W was stable for 28 days at 25 °C and between 2 and 8 °C. These stability data allow preparations to be made in advance. The remainder of the cabazitaxel vial fitted with a Spike was stable for 28 days at 25 °C, allowing the remainder of the vial to be used over several days.
Subject
Pharmacology (medical),Pharmacology,Pharmacy
Reference16 articles.
1. Cabazitaxel Zentiva 20 mg/ml concentrate for solution for infusion. In: Summary of product characteristics Updated 29-Oct-2021: Zentiva. Available from: https://www.medicines.org.uk/emc/product/13007/smpc
2. Jevtana® 60 mg concentrate and solvent for solution for infusion. Summary of Product Characteristics Updated 21-June-2022. Available from: https://www.medicines.org.uk/emc/product/4541.
3. Cabazitaxel Tillomed 60 mg concentrate and solvent for solution for infusion. In: Summary of product characteristics. Updated 08-Feb-2022: Tillomed Laboratories Ltd.
4. Cabazitaxel EVER pharma 10 mg/ml concentrate for solution for infusion. Summary of Product Characteristics Updated 30-Jun-2021. EVER Valinject GmbH/Kent Pharma UK Ltd. Available from: https://www.medicines.org.uk/emc/product/12687/smpc.
5. Cabazitaxel accord healthcare limited 20 mg/ml concentrate for solution for infusion. Summary of Product Characteristics Updated 18-August-2022. Available from: https://www.medicines.org.uk/emc/product/12332/smpc.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献